Adverse Event Reporting

To report an adverse event or a product complaint about Mysimba®, please contact:

HPRA Pharmacovigilance,
Earlsfort Terrace,
Dublin 2
Tel: +353 1 6764971;
Fax: +353 1 6762517;
Website: www.hpra.ie;
E-mail: medsafety@hpra.ie

Adverse events should also be reported to Orexigen®:
Tel: +001-800-902-210;
E-mail: Mysimba@druginfo.com.

IE-MYS-67 | Date of preparation: October 2019

Mysimba®is subject to additional monitoring. To report an adverse event or a product complaint about Mysimba®, please contact: HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517; Website: www.hpra.ie; e-mail: medsafety@hpra.ie Adverse events should also be reported to Adverse events should also be reported to Nalpropion Pharmaceuticals LLC®: 1-800- 902-210 or Mysimba@druginfo.com.

For all other queries, please contact our Irish office at Tel: +353 (0)1 2057760, Fax: +353 (0)1 2698919 or irishoffice@consilienthealth.com

The information on this website is intended for healthcare professionals registered in the Republic of Ireland only.

Mysimba® is a registered trademark of Nalpropion Pharmaceuticals LLC

© 2020 Nalpropion Pharmaceuticals LLC

Other trademarks, registered or otherwise, are the property of their respective owners.